Anthrax: clinical features, pathogenesis, and potential biological warfare threat.
about
Rapid, sensitive, and specific lateral-flow immunochromatographic device to measure anti-anthrax protective antigen immunoglobulin G in serum and whole bloodShort-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthraxBinary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteinsBacillus anthracisAnthrax pathogen evades the mammalian immune system through stealth siderophore productionAnthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxinAnthrax Toxins in Context of Bacillus anthracis Spores and Spore GerminationNovel strategies for enhanced removal of persistent Bacillus anthracis surrogates and Clostridium difficile spores from skinIdentification of a surrogate marker for infection in the African green monkey model of inhalation anthraxStable dry powder formulation for nasal delivery of anthrax vaccineEfficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthraxRabbit and nonhuman primate models of toxin-targeting human anthrax vaccinesEvaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.Early indicators of exposure to biological threat agents using host gene profiles in peripheral blood mononuclear cellsActivity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax modelRole of purine biosynthesis in Bacillus anthracis pathogenesis and virulence.A case of septicaemic anthrax in an intravenous drug userAnthrax lethal toxin impairs CD1d-mediated antigen presentation by targeting the extracellular signal-related kinase 1/2 mitogen-activated protein kinase pathway.Anthrax lethal factor inhibitionInduction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.Human transferrin confers serum resistance against Bacillus anthracisEfficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection.Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.Bacillus anthracis virulence in Guinea pigs vaccinated with anthrax vaccine adsorbed is linked to plasmid quantities and clonalityPhase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.Fully virulent Bacillus anthracis does not require the immunodominant protein BclA for pathogenesis.Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.Development of an inhalational Bacillus anthracis exposure therapeutic model in cynomolgus macaquesDisrupting the luxS quorum sensing gene does not significantly affect Bacillus anthracis virulence in mice or guinea pigs.Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia.Glycerol monolaurate inhibits the effects of Gram-positive select agents on eukaryotic cells.A Cumulative Spore Killing Approach: Synergistic Sporicidal Activity of Dilute Peracetic Acid and Ethanol at Low pH Against Clostridium difficile and Bacillus subtilis SporesTetrazole-Based trans-Translation Inhibitors Kill Bacillus anthracis Spores to Protect Host Cells.Bacillus anthracis spores of the bclA mutant exhibit increased adherence to epithelial cells, fibroblasts, and endothelial cells but not to macrophages.Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.Non-canonical effects of anthrax toxins on haematopoiesis: implications for vaccine development.
P2860
Q23919993-A4ACB7C0-936B-48D1-859F-7EDCDA02CAADQ24546050-8E2830B9-3FDB-4DA5-BC3C-1FB2F7E36FB5Q24562788-FC970DD7-E6BE-41F7-AFF3-9402D5C175C4Q24672893-A94C5BF9-1322-46F9-B8A9-D51DA4A1FBFBQ24675112-6188AF75-6DD3-4CE5-BA20-2FED6512175AQ24796044-2125296F-E666-44A1-9D98-5BC14BCF5814Q26796601-94D00B96-9FBA-4F7D-ABA3-73C60CC442DEQ28385028-CF868F24-C1AA-42D6-A881-8F464C751BC0Q28386270-572B0F42-5B45-4815-897B-E4E9D5E32E92Q28386405-6F57D7A4-1332-4558-909E-EA3D11AD6AA9Q28389738-BA44434C-DF18-44D7-9700-2F12818ED9DCQ28398013-06295A66-29B1-47DD-B4D1-C9F055F2CF7BQ30152051-395FAA96-06EC-4472-B47B-882393F94836Q33356244-BEBB3EDC-DB15-4A9A-B52C-38C19B2C474FQ33676316-D0D1EE47-E1C9-4FE1-8813-D44F185AB875Q33735602-97127054-114A-47E3-8D15-40FC151E2092Q33798633-B0500D84-53C3-4373-9EB7-848B5D74B5B0Q33826054-FA8286A9-7C65-49DD-83B2-D35F62817E40Q33833525-76DBF323-0166-441F-A8B9-DBBC4DD35EC3Q34033557-BAEF3B47-2724-43F1-B029-F94D85D290CAQ34107185-A30FF758-5AE0-4ABD-97C8-016F9F735C9CQ34150994-099C17A6-555D-4F26-9DF3-D512E92C8FDCQ34301043-8B9CCF60-1625-48F1-AB34-53027068869EQ34575393-FDB8554A-3DCD-4F33-85F4-3A2742CC9345Q34774876-721FF50A-E77D-4031-9816-C17B8C1F81EEQ35598157-4057D929-6318-4C31-9686-C931702F8C27Q35688979-90F99954-ABF1-4935-9BC4-8E2AA5E688A6Q36313211-48F35DB6-39B9-483B-98AE-C11FAFCFDE2BQ36378610-552079ED-526F-471D-910B-EC88D6A563CBQ36472130-17EE504D-06DD-4265-88C4-97300D4DFD68Q36523135-8775785A-F601-40C2-86B5-0AAEEB0169FAQ36910011-633C8409-1E20-42EB-AE1A-847A344684CEQ38377359-482CFB5A-AD3F-4830-957F-3A359BB10985Q38650833-FC45DF03-1B0D-4BA2-8DD2-3BA23EE52293Q40112607-1740E774-5DBE-4EF3-B0A6-8AC538341089Q40345358-74C7908F-19C0-4649-8631-696088813374Q42919729-843D34A8-BE3B-4ADB-B3C9-FF38D3C89AA8
P2860
Anthrax: clinical features, pathogenesis, and potential biological warfare threat.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Anthrax: clinical features, pathogenesis, and potential biological warfare threat.
@ast
Anthrax: clinical features, pathogenesis, and potential biological warfare threat.
@en
Anthrax: clinical features, pathogenesis, and potential biological warfare threat.
@nl
type
label
Anthrax: clinical features, pathogenesis, and potential biological warfare threat.
@ast
Anthrax: clinical features, pathogenesis, and potential biological warfare threat.
@en
Anthrax: clinical features, pathogenesis, and potential biological warfare threat.
@nl
prefLabel
Anthrax: clinical features, pathogenesis, and potential biological warfare threat.
@ast
Anthrax: clinical features, pathogenesis, and potential biological warfare threat.
@en
Anthrax: clinical features, pathogenesis, and potential biological warfare threat.
@nl
P1476
Anthrax: clinical features, pathogenesis, and potential biological warfare threat
@en
P2093
Friedlander AM
P304
P577
2000-01-01T00:00:00Z